Background: Outcomes after hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) are better when HCT is performed during first complete remission (CR1). This study aimed to identify and address knowledge gaps that affect the timely referral of patients for HCT consultation. Methods: A mixed-methods educational needs assessment included a national survey and focus groups consisting of hematologists/oncologists. An educational intervention of 3 webinars addressed identified knowledge gaps. Results: A total of 150 hematologists/oncologists were recruited for the survey, of whom 20 participated in focus groups. Physicians in practice 0 to 10 years were 4.2 times more likely to refer for HCT consultation in CR1 than those with >10 years in practice (P=.0027). Physicians seeing ≤10 patients with AML in the past year were 3.7 times more likely to refer for HCT consultation in CR1 than those seeing >10 patients (P=.0028). Knowledge gaps included (1) improper classification of molecular/cytogenetic results for risk stratification, (2) lack of understanding that disease stage impacts outcomes, and (3) use of chronologic age alone for referral decision-making. Combined attendance for the webinars was 1,098 clinicians; >74% of participants indicated that they would apply the knowledge they gained in clinical practice. Trends were observed toward improvement in identifying favorable-risk AML, from 48% to 60% (n=85; P=.12); improvement in identifying 2 poor-risk cytogenetic/molecular abnormalities, with the percentage of respondents indicating chromosome 7 deletion increasing from 51% to 70% (n=53; P=.05) and that of respondents indicating TP53 mutation increasing from 42% to 62% (n=62; P=.03); and improvement in identifying which patients with AML aged >60 years were most likely to benefit from HCT based on cytogenetic/molecular features, with the percentage of correct responses increasing from 66% to 81% (n=62; P=.07). Conclusions: The webinars met the educational needs of learners and improved knowledge gaps. This study provided novel insights into the learning needs of clinicians who care for patients with AML and a roadmap for future educational interventions.
Submitted November 2, 2018; accepted for publication June 6, 2019.
Author contributions:Study concept and design: All authors. Data analysis: Meyer, Mau, Burns. Manuscript preparation: All authors. Manuscript approval: All authors.
Disclosures: Ms. Haven has disclosed that she owned stock in Pfizer during the study. Ms. Foster has disclosed that her spouse owned stock in Pfizer during the study. The remaining authors have disclosed that they have not received any financial considerations from any person or organization to support the preparation, analysis, results, or discussion of this article.
Correspondence: Linda J. Burns, MD, National Marrow Donor Program/Be the Match, CIBMTR Health Services Research Program—Minneapolis, 500 North 5th Street, Minneapolis, MN 55401-1206. Email: email@example.com
YaoS, HahnT, ZhangY, . Unrelated donor allogeneic hematopoietic cell transplantation is underused as a curative therapy in eligible patients from the United States. Biol Blood Marrow Transplant2013;19:1459–1464.
YaoS, HahnT, ZhangY, . Unrelated donor allogeneic hematopoietic cell transplantation is underused as a curative therapy in eligible patients from the United States. Biol Blood Marrow Transplant 2013;19:1459–1464.2381153710.1016/j.bbmt.2013.06.014)| false
KorethJ, SchlenkR, KopeckyKJ, . Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA2009;301:2349–2361.
D’SouzaA, FrethamC. Current uses and outcomes of hematopoietic stem cell transplantation: CIBMTR summary slides, 2017. Available at: http://www.cibmtr.org. Accessed October 13, 2018.
HahnT, McCarthyPLJr, HassebroekA, . Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol2013;31:2437–2449.
HahnT, McCarthyPLJr, HassebroekA, . Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol 2013;31:2437–2449.10.1200/JCO.2012.46.619323715573)| false
CookDA, LevinsonAJ, GarsideS, . Instructional design variations in internet-based learning for health professions education: a systematic review and meta-analysis. Acad Med 2010;85:909–922.2052004910.1097/ACM.0b013e3181d6c319)| false
FordisM, KingJE, BallantyneCM, . Comparison of the instructional efficacy of internet-based CME with live interactive CME workshops: a randomized controlled trial. JAMA 2005;294:1043–1051.10.1001/jama.294.9.104316145024)| false
CookDA, ThompsonWG, ThomasKG, . Impact of self-assessment questions and learning styles in web-based learning: a randomized, controlled, crossover trial. Acad Med 2006;81:231–238.10.1097/00001888-200603000-0000516501263)| false
KemperKJ, GardinerP, GobbleJ, . Randomized controlled trial comparing four strategies for delivering e-curriculum to health care professionals [ISRCTN88148532]. BMC Med Educ 2006;6:2.1640573410.1186/1472-6920-6-2)| false